{"nctId":"NCT02629965","briefTitle":"Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients","startDateStruct":{"date":"2016-02-12","type":"ACTUAL"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"count":184,"armGroups":[{"label":"tiotropium + olodaterol","type":"EXPERIMENTAL","interventionNames":["Drug: tiotropium","Drug: olodaterol"]},{"label":"tiotropium","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: tiotropium"]}],"interventions":[{"name":"tiotropium","otherNames":[]},{"name":"olodaterol","otherNames":[]},{"name":"tiotropium","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* All patients must sign an informed consent consistent with International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines prior to participation in the trial, which includes medication washout and restrictions.\n* All patients must have a diagnosis of chronic obstructive pulmonary disease (COPD) and must meet the following spirometric criteria:\n\nPatients must have relatively stable airway obstruction with a post-bronchodilator Forced expiratory volume in one second (FEV1) \\< 80% of predicted normal and post-bronchodilator FEV1/forced vital capacity (FVC) \\< 70% at Visit 1.\n\n* Male or female patients, aged \\>= 40 years.\n* Patients must be current or ex-smokers with a smoking history of more than 10 pack years. Patients who have never smoked cigarettes must be excluded.\n* Patients with score on the modified Medical Research Council (mMRC) \\>= 1.\n* Patients who walk \\< 400 meters of 6MWT and have a score on the modified Borg \\>= 4 at the end of 6 minute walk test (6MWT) at Visit 2.\n* Patients must be able to perform technically acceptable pulmonary function tests (spirometry), to use the physical activity monitor and must be able to complete 6MWT during the study period as required in the protocol.\n* Patients must be able to inhale medication in a competent manner from the RESPIMAT Inhaler and from a metered dose inhaler.\n\nExclusion criteria:\n\n* Patients with a significant disease other than COPD; a significant disease is defined as a disease which, in the opinion of the investigator, may put the patient at risk because of participation in the study, influence the results of the study and cause concern regarding the patient's ability to participate in the study.\n* Patients with clinically relevant abnormal baseline haematology, blood chemistry,urinalysis or creatinine \\> x2 upper limit of normal (ULN) will be excluded regardless of clinical condition (a repeat laboratory evaluation can be conducted if deemed necessary by the investigator).\n* Patients with a current documented diagnosis of asthma. For patients with allergic rhinitis or atopy, source documentation is required to verify that the patient does not have asthma.\n* Further exclusion criteria apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Inspiratory Capacity at Rest Measured at 60 Minutes Post-dose","description":"At day 43 inspiratory capacity at rest measured at 60 minutes post-dose, after 6 weeks of each treatment. Adjusted mean was entered instead of mean in statistical analysis.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.875","spread":"0.019"},{"groupId":"OG001","value":"1.990","spread":"0.019"}]}]}]},{"type":"SECONDARY","title":"6-minute Walk Distance [Meter]","description":"6-minute walk distance \\[Meter\\] treatment comparisons after 6 weeks of each treatment. Adjusted mean was entered instead of mean in statistical analysis.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"307.356","spread":"5.170"},{"groupId":"OG001","value":"311.524","spread":"5.170"}]}]}]},{"type":"SECONDARY","title":"Average Number of Step Per Day (Step/Day)","description":"At day 43 adjusted mean (SE) of average number of step per day \\[step/day\\] treatment comparisons in measured by the activity monitor in 2 weeks prior to Week 6 of each treatment. Adjusted mean was entered instead of mean in statistical analysis.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3550.400","spread":"93.123"},{"groupId":"OG001","value":"3559.901","spread":"93.460"}]}]}]},{"type":"SECONDARY","title":"Average Daily Duration (Minutes) of ≥ 4 Metabolic Equivalents (METs)","description":"At day 43 adjusted mean (SE) of average daily duration \\[minute\\] of ≥ 4 METs treatment comparisons measured by the activity monitor in the 2 weeks prior to week 6 of each treatment. Adjusted mean was entered instead of mean in statistical analysis.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.206","spread":"0.497"},{"groupId":"OG001","value":"9.914","spread":"0.499"}]}]}]},{"type":"SECONDARY","title":"Average Daily Duration (Minutes) of ≥ 3 Metabolic Equivalents (METs)","description":"At day 43 adjusted mean (SE) of average daily duration \\[minute\\] of ≥ 3 METs treatment comparisons measured by the activity monitor in 2 weeks prior to Week 6 of each treatment. Adjusted mean was entered instead of mean in statistical analysis.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.662","spread":"0.979"},{"groupId":"OG001","value":"45.601","spread":"0.979"}]}]}]},{"type":"SECONDARY","title":"Average Daily Duration (Minutes) of ≥ 2 Metabolic Equivalents (METs)","description":"At day 43 adjusted mean (SE) of average daily duration \\[minute\\] of ≥ 2 METs treatment comparison measured by the activity monitor in 2 weeks prior to Week 6 of each treatment. Adjusted mean was entered instead of mean in statistical analysis.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"171.935","spread":"2.506"},{"groupId":"OG001","value":"174.192","spread":"2.517"}]}]}]},{"type":"SECONDARY","title":"Average Daily Active Strength (Metabolic Equivalents*Minutes) of ≥ 3 METs","description":"At day 43 adjusted mean (SE) of average daily active strength \\[METs x minute\\] of \\>=3 METs treatment comparisons measured by the activity monitor in 2 weeks prior to Week 6 of each treatment. Adjusted mean was entered instead of mean in statistical analysis.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"148.647","spread":"3.723"},{"groupId":"OG001","value":"151.067","spread":"3.737"}]}]}]},{"type":"SECONDARY","title":"60 Minutes Post-dose Slow Vital Capacity (SVC) (in Litre)","description":"At day 43 adjusted mean (SE) of 60 minute post-dose slow vital capacity \\[Litre\\] treatment comparisons after 6 weeks of each treatment. Adjusted mean was entered instead of mean in statistical analysis.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.962","spread":"0.021"},{"groupId":"OG001","value":"3.096","spread":"0.021"}]}]}]},{"type":"SECONDARY","title":"30 Minutes Post-dose Forced Expiratory Volume in One Second (FEV1) (in Litre)","description":"At day 43 adjusted mean (SE) of 30 minute post-dose forced expiratory volume in one second (FEV1) \\[Litre\\] treatment comparisons after 6 weeks of each treatment. Adjusted mean was entered instead of mean in statistical analysis.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.169","spread":"0.011"},{"groupId":"OG001","value":"1.275","spread":"0.011"}]}]}]},{"type":"SECONDARY","title":"30 Minutes Post-dose Forced Vital Capacity (FVC) (in Litre)","description":"At day 43 adjusted mean (SE) of 30 minute post-dose forced vital capacity (FVC) \\[Litre\\] treatment comparisons after 6 weeks of each treatment. Adjusted mean was entered instead of mean in statistical analysis.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.857","spread":"0.021"},{"groupId":"OG001","value":"3.020","spread":"0.021"}]}]}]},{"type":"POST_HOC","title":"Inspiratory Capacity [Litre] Treatment Comparisons of 6-Minute Walk Test (6MWT) Completer at Treatment Period","description":"At day 43 adjusted mean (standard error) of inspiratory capacity \\[Litre\\] test comparisons after 6 weeks of each treatment for 6MWT completer at treatment period. Adjusted mean was entered instead of mean in statistical analysis.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.940","spread":"0.022"},{"groupId":"OG001","value":"2.072","spread":"0.022"}]}]}]},{"type":"POST_HOC","title":"Inspiratory Capacity [Litre] Treatment Comparisons of 6-Minute Walk Test (6MWT) Completer at Baseline Period","description":"At day 43 adjusted mean (standard error) of inspiratory capacity \\[Litre\\] test comparisons after 6 weeks of each treatment for 6MWT completer at baseline period. Adjusted mean was entered instead of mean in statistical analysis.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.925","spread":"0.021"},{"groupId":"OG001","value":"2.053","spread":"0.021"}]}]}]},{"type":"POST_HOC","title":"Inspiratory Capacity [Litre] Test Comparisons of 6-Minute Walk Treatment (6MWT) in-Completer at Treatment Period","description":"At day 43 adjusted mean (standard error) of inspiratory capacity \\[Litre\\] test comparisons after 6 weeks of each treatment for 6MWT in-completer at treatment period. Adjusted mean was entered instead of mean in statistical analysis.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.738","spread":"0.024"},{"groupId":"OG001","value":"1.820","spread":"0.024"}]}]}]},{"type":"POST_HOC","title":"Inspiratory Capacity [Litre] Treatment Comparisons of 6-Minute Walk Test (6MWT) in-Completer at Baseline Period","description":"At day 43 adjusted mean (standard error) of inspiratory capacity \\[Litre\\] test comparisons after 6 weeks of each test for 6MWT in-completer at baseline period. Adjusted mean was entered instead of mean in statistical analysis.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.744","spread":"0.026"},{"groupId":"OG001","value":"1.830","spread":"0.026"}]}]}]},{"type":"POST_HOC","title":"Inspiratory Capacity [Litre] Treatment Comparisons of Subgroup of Global Initiative for Chronic Obstructive Lung Disease (GOLD) Stage I/II","description":"At day 43 adjusted mean (standard error) of inspiratory capacity \\[Litre\\] treatment comparisons after 6 weeks of each treatment for subgroup of GOLD stage I/II. Adjusted mean was entered instead of mean in statistical analysis.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.023","spread":"0.023"},{"groupId":"OG001","value":"2.106","spread":"0.023"}]}]}]},{"type":"POST_HOC","title":"Inspiratory Capacity [Litre] Treatment Comparisons of Subgroup of Global Initiative for Chronic Obstructive Lung Disease (GOLD) Stage III/IV","description":"At day 43 adjusted mean (standard error) of inspiratory capacity \\[Litre\\] treatment comparisons after 6 weeks of each treatment for subgroup of GOLD stage III/IV. Adjusted mean was entered instead of mean in statistical analysis.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.697","spread":"0.026"},{"groupId":"OG001","value":"1.849","spread":"0.026"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":182},"commonTop":["Viral upper respiratory tract infection"]}}}